17 results about "Calcineurin" patented technology

The present invention relates to the use of cannabidiol (CBD) in the treatment of patients with childhood-onset epilepsy who are concurrently taking immunosuppressant drugs. In particular the immunosuppressant drug is a calcineurin inhibitor. More particularly the immunosuppressant drug is tacrolimus. Where the CBD is used in combination with an immunosuppressant drug, caution should be taken. For example, the dose of either the CBD and / or the immunosuppressant drug may be required to be reduced. Moreover, the patient may need to be monitored for side effects of said drug-drug interaction. Preferably the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w / w) and the other components of the extract are characterised. In particular the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w / w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.

The application provides a nanobody targeting human transmembrane activator and calcium modulator and cyclophilin interactor (TACI) and an application thereof, and the antibody is derived from a llama heavy chain antibody variable region. The anti-TACI single-domain antibody NB38 can specifically bind to human TACI with high affinity, can recognize a recombinant TACI protein, can also recognize a TACI with a natural conformation on a cell surface, and can partially block a BAFF / APRIL signal pathway. Based on the nanobody, the application constructs a fusion protein, a chimeric antigen receptor, an effector cell expressing the chimeric antigen receptor, and a double-specific cell linker and other genetically engineered forms. The nanobody can be further extended into a drug coupling form. The product of the application can be used for mediating directional recognition and killing of TACI positive cells, and can be used as a supplement and expansion of BCMA targeted therapy, and provides a new candidate technical scheme for targeted therapy of multiple myeloma and other TACI related diseases.

The application provides novel N-heterocyclic compounds, such as quinoline or isoquinoline compounds, preferably quinazoline compounds, as calcineurin inhibitors (CNIs,) that provide improved safety profiles, and the pharmaceutical composition and formulation thereof, as well as a method of using the N-heterocyclic compounds for the treatment of, inter alia, an inflammatory-related disease or disorder.

This specification provides compositions and dosing regimens of calcineurin inhibitors and cytochrome p450 inhibitors. The present invention provides, for example, a method of treating an allogeneic immune, autoimmune, inflammatory, or mitochondrial condition in a subject, the method comprising administering a calcineurin inhibitor and a cytochrome p450 inhibitor to the subject according to an intermittent dosing schedule. In one embodiment, the calcineurin inhibitor and the cytochrome p450 inhibitor are administered once a week.

The present invention provides synthetic peptides capable of binding to calcineurin, having a length of about 14-20 amino acids, having at least 1 amino acid difference from any natural peptide sequence. The present invention further provides compositions including such peptides and uses thereof. Further provided are methods and systems for designing such binding peptides.

Graft-versus-host disease (GVHD) prophylaxis often consists of calcineurin inhibitor-based combinations that indiscriminately curtail T cell receptor signal transduction. This broad inactivation consequently impairs the function of alloreactive pathogenic T cells as well as beneficial regulatory T cells (Treg) and anti-tumor cytotoxic T lymphocytes (CTL). Due to this non-selective approach, GVHD prevention is incomplete and the graft-versus-leukemia (GVL) effect is jeopardized. Disclosed are isolated binding molecules that disrupt the interaction of DLL4 and Notchl and methods of their use, including, but not limited to the treatment of graft versus host disease.

The application discloses application of pulegone as an effective component in an immunosuppressant, and the pulegone with significant calcineurin (CN) inhibiting activity is screened from the Schleichera oleosa Kurz, the immunosuppressive effect of the pulegone is equivalent to that of cyclosporine A which is widely used in clinic, mechanism research shows that the pulegone targets CN / NFAT signal path to play the immunosuppressive activity, and the pulegone has very weak cytotoxicity to spleen cells, and is a high-efficiency and low-toxicity immunosuppressant.

Disclosed herein are conditional siRNAs activatable by pro-hypertrophic RNA sequences and use thereof for treating conditions such as cardiac hypertrophy. The conditional siRNAs target calcineurin or HDAC2.

The present application provides a kind of pharmaceutical composition for vulvar sclerosing lichen and its preparation method, the pharmaceutical composition includes active ingredient and pharmaceutically acceptable vulva local administration adjuvant, active ingredient is made of 0.005-0.02 parts of mometasone furoate, 0.05-0.3 parts of calcineurin inhibitor, 0.5-2 parts of paeoniflorin, 0.8-3 parts of asiaticoside, 0.3-1.5 parts of recombinant collagen, 0.2-1 part of ginkgolide B.The present application is aimed at the core pathogenesis of disease, constructs multi-target whole course of disease synergistic therapy system, can realize anti-inflammatory regulation, anti-fibrosis, basement membrane repair, microcirculation improvement simultaneously, low-dose strong effect, greatly reduce side effect and recurrence rate;Liposome targeted delivery technology is used, the stability of active ingredient is guaranteed, process controllable adaptation industrialization production, and clinical application prospect is wide.

The application provides novel N-heterocyclic compounds, such as quinoline or isoquinoline compounds, preferably quinazoline compounds, as calcineurin inhibitors (CNIs,) that provide improved safety profiles, and the pharmaceutical composition and formulation thereof, as well as a method of using the N-heterocyclic compounds for the treatment of, inter alia, an inflammatory-related disease or disorder.

The invention provides a nano antibody targeting human transmembrane activator and calmodulin TACI (transmembrane activator and calmodulin phosphatase) interaction protein and application of the nano antibody. The antibody is derived from an alpaca heavy-chain antibody variable region. The anti-TACI single-domain antibody NB38 can be combined with human TACI with high affinity and specificity, can recognize recombinant TACI protein, can also recognize TACI with native conformation on the surface of a cell, and can partially block a BAFF / APRIL signal channel. Based on the nano antibody, gene engineering forms such as fusion protein, a chimeric antigen receptor, effector cells for expressing the chimeric antigen receptor, a bispecific cell connector and the like are constructed. The nano antibody can be further expanded into a coupled drug form. The product can be used for mediating directional recognition and killing of TACI positive cells, can be used as supplement and expansion of BCMA targeted therapy, and provides a new candidate technical scheme for targeted therapy of multiple myeloma and other TACI related diseases.

Described are peptides and peptide conjugates comprising CN binding motifs (CNBM) which inhibit the CN-NFAT interaction. In some embodiments, the peptides comprise: (i) CNBM; (ii) a hydrophobic, non-peptidic moiety (RH) which interacts with the hydrophobic pocket on a CN protein; (iii) a sequence -AAU1-AAU2-AAU3-AAU4-AAU5-AAU6-, wherein each of AAU2, AAU3, AAU4, AAU5, and AAU6, is, independently, optional, and each of AAU1, AAU2, AAU3, AAU4, AAU5, and AAU6 when present is independently an amino acid as defined herein; or (iv) combinations thereof. In some embodiments, RH is conjugated to the N- or C-terminus of the CNBM. In some embodiments, the sequence -AAU1-AAU2-AAU3-AAU4-AAU5-AAU6- is conjugated to the N- or C terminus of the CNBM. In some embodiments, the peptides comprise: CNBM and RH. In some embodiments. In some embodiments, the peptides comprise: CNBM and AAU1-AAU2-AAU3-AAU4-AAU5-AAU6-. In some embodiments, the peptides of the disclosure CNBM and RH.

The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.

Provided herein are compositions and dosing regimens of a calcineurin inhibitor and a cytochrome p450 inhibitor.

Provided herein are compositions and dosing regimens of a calcineurin inhibitor and a cytochrome p450 inhibitor.

The present disclosure provides modified cells including pluripotent stem cells, hematopoietic precursor cells, and hematopoietic cells (e.g., modified Tregs) that are steroid and / or calcineurin inhibitor-resistant. The present disclosure provides methods for generating steroid and / or calcineurin inhibitor-resistant modified cells including pluripotent stem cells, hematopoietic precursor cells, and hematopoietic cells. Also provided herein are compositions and methods of treatment.

The invention belongs to the technical field of medicines, discloses a protein, a preparation method, a pharmaceutical composition and application, and particularly relates to a protein BmP01, a nucleic acid molecule for encoding the protein, a recombinant vector containing the nucleic acid molecule and a host cell containing the expression vector or genome integrated with the nucleic acid molecule. The invention further discloses a preparation method and pharmacological activity of the natural protein BmP01, the biosynthetic protein rBmP01 and the solid-phase synthetic protein sBmP01, and application of the proteins, nucleic acid molecules, expression vectors, host cells or pharmaceutical compositions in preparation of anti-epilepsy treatment drugs and research of calmodulin inhibitors.